
Lina Khan, a progressive champion nominated by President Biden for a key enforcement post, wants to transform antitrust policy into a bulwark against corporate power by blocking more mergers, attacking monopolistic practices and potentially breaking up some of America’s largest companies, reported The Wall Street Journal.
Ms. Khan, 32 years old, is awaiting Senate confirmation for a Democratic seat on the five-member Federal Trade Commission (FTC) after she was cleared by the Senate Commerce Committee. She has risen to prominence—and gained bipartisan support—as Democrats and Republicans alike have said lax antitrust enforcement, especially in the tech sector, has allowed dominant firms to hobble rivals and stifle competition.
Her targets have included not just Big Tech, but also Big Chocolate and others. She has argued for hawkish positions that would overhaul legal doctrine and go well beyond the approach of recent antitrust enforcers. While her most ardent supporters believe such changes are long overdue, her views have prompted a debate on whether her approach is realistic and potentially so sweeping that it could prove jarring to the economy.
“Stepped-up antitrust enforcement is one thing,” said Howard University law professor Andrew Gavil, who was a top FTC staffer the last time Democrats controlled the Commission. “Changing the standards is a different matter,” he said.
Mr. Gavil, who favors more enforcement, said Ms. Khan will have to consider how to translate her views into something that can be applied in practice. “That’s more challenging than simply being a critic on the outside,” he said.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Moves to Dismiss FTC Antitrust Case Amid Ongoing Trial
May 18, 2025 by
CPI
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas